Skip to content

DASL-HiCaP: Darolutamida melhora a sobrevida livre de metástases no câncer de próstata | ESMO 2026

More on genitourinary cancers

Everything on genitourinary cancers

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26
Dr. Daniel Heng. Trial update. ESMO 2026.
Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026
Dr. Andrea Necchi. ESMO 2026. Trial update.
VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
Dr. Tom Powles. Trial update. ESMO 2026.
Can triplet combinations improve outcomes in advanced urothelial cancer?
Sara Coca Membribes. ESMO 2026. Expert pick. Day 1.
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Publication pick. Nature Reviews Urology. October 15, 2026.
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR)
Publication pick. Journal of Clinical Oncology. October 12, 2026.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details